On the other hand, ibrutinib’s off-target inhibition of JAK3, ITK, and EGFR means that it can target oncogenic pathways other than BTK in tumor cells and act as a T-cell modulator in combination immunotherapy [96,97,98,99]. Here, BTK is linked to neoplasm.